RANZCOG and ACOG release new menopause guidelines
Medical organizations in Australia and the United States released distinct clinical guidelines governing menopausal hormone therapy, setting new frameworks for managing vasomotor symptoms while addressing ongoing treatment shortages and online misinformation.
-
Key Clinical Takeaways:
- RANZCOG released its first evidence-based menopause guidelines in Australia to establish standardized clinical care for women aged 40 and above.
- ACOG updated its United States guidance for the first time in over a decade, positioning hormone replacement therapy as a first-line option for hot flashes and night sweats.
- Supply chain constraints for hormone replacement patches have forced patients to ration doses while clinicians sort through conflicting online health claims.
Clinical Guidelines and Standardization Efforts in Australia
The Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG) published evidence-based clinical guidelines designed to clarify treatment options for menopausal symptoms in women aged 40 and above, as reported by abc.net.au. The framework covers vasomotor symptoms such as hot flushes and night sweats alongside genito-urinary indicators like vaginal dryness and urinary frequency. RANZCOG guideline development group chair Catriona Melville stated that the initiative aims to cut through online misinformation and equip clinicians with clear safety data for patient discussions. Magdalena Simonis, a practising general practitioner and women’s health expert from the University of Melbourne, emphasized that the guidelines reinforce holistic care, including cholesterol lipid control and bone density management. Meanwhile, Sarah White, chief executive of Jean Hailes for Women’s Health, noted that the structured advice helps professionals offer reliable support despite persistent information noise.
Hormone Replacement Therapy Updates in the United States
The American College of Obstetricians and Gynecologists (ACOG) shifted its clinical advice for the first time in more than a decade, recommending hormone replacement therapy as a primary treatment for moderate-to-severe vasomotor symptoms, according to CBS News. Dr. Kameelah Phillips, an OB-GYN and menopause specialist, stated that therapies involving estrogen and progesterone represent a mainstream return away from older, less effective alternatives. Treatment options span pills, patches, sprays, gels, and vaginal rings designed to stabilize hormone drops occurring in a patient’s late forties or early fifties. Eligibility restrictions remain for individuals with personal histories of breast cancer, blood clots, stroke, or liver disease. Dr. Céline Gounder, a medical contributor for CBS News, explained that historical safety concerns stemmed from a 2002 long-term study focused on older patient demographics, whereas contemporary protocols favor initiating treatment before age 60 or within 10 years of onset.
HRT Patch Shortages Persist Until Year End
Supplies of hormone replacement therapy patches remain tight, with availability projected to normalize no earlier than the end of the year, according to abc.net.au reporting. The shortage has led some patients to divide patches in half to stretch remaining supplies. For individuals contraindicated for hormone therapy due to prior breast cancer diagnoses, the Australian guidelines outline that vaginal oestrogen can be utilized safely. For those unable to use hormones, non-hormonal alternatives and specialized consultations remain available through healthcare providers, as noted by Dr. Kameelah Phillips.
Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.
